Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) COO Sells $22,059.20 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) COO Alistair Milnes sold 3,244 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $6.80, for a total value of $22,059.20. Following the completion of the sale, the chief operating officer owned 140,133 shares in the company, valued at approximately $952,904.40. The trade was a 2.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Alistair Milnes also recently made the following trade(s):

• On Monday, January 5th, Alistair Milnes sold 3,416 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total value of $22,067.36.

Bicycle Therapeutics Price Performance

BCYC stock opened at $6.63 on Friday. The business’s 50-day moving average is $6.90 and its two-hundred day moving average is $7.41. The firm has a market capitalization of $459.91 million, a P/E ratio of -1.83 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a 1 year low of $6.03 and a 1 year high of $15.43.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. The firm had revenue of $11.73 million for the quarter, compared to analyst estimates of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. On average, analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

Wall Street Analysts Forecast Growth

BCYC has been the subject of several recent analyst reports. Citizens Jmp lifted their price objective on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Friday, October 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a research report on Friday, October 31st. Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 target price (down previously from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $19.73.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC lifted its stake in Bicycle Therapeutics by 6.4% in the third quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock valued at $23,050,000 after buying an additional 178,000 shares during the last quarter. Westfield Capital Management Co. LP grew its position in shares of Bicycle Therapeutics by 6.2% during the third quarter. Westfield Capital Management Co. LP now owns 2,952,543 shares of the company’s stock worth $22,853,000 after acquiring an additional 172,052 shares during the last quarter. Long Focus Capital Management LLC increased its holdings in shares of Bicycle Therapeutics by 7.7% in the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after acquiring an additional 101,402 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Bicycle Therapeutics by 64.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after acquiring an additional 451,135 shares during the period. Finally, Tybourne Capital Management HK Ltd. raised its position in Bicycle Therapeutics by 72.4% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after purchasing an additional 417,400 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.